[{"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-001", "question": "A 58-year-old man undergoes pancreaticoduodenectomy for a 2.5 cm pancreatic head adenocarcinoma. On postoperative day 3, his closed-suction drain has serous output of 25 mL/24 hours. Drain fluid amylase is 1,200 U/L (serum amylase 150 U/L). He is afebrile, hemodynamically stable, with soft abdomen and no leukocytosis. What is the most appropriate next step in management?", "options": ["Remove the drain", "Keep the drain and start octreotide", "Obtain contrast-enhanced CT of abdomen", "Keep the drain and discharge to home", "Return to operating room for exploration"], "answer": "A", "answer_index": 0, "explanation": "The 2016 ISGPS update defines a 'biochemical leak' as drain fluid amylase >3x serum on POD 1-3 with output <30 mL/day and no clinical sequelae, which can be managed by drain removal. Grade B fistula requires output >30 mL/day or clinical impact. The high amylase alone does not mandate retention if output remains low and the patient is clinically well.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": The question asks for the next step in management of a post-pancreaticoduodenectomy patient with a biochemical leak (drain fluid amylase >3× serum, low output, no clinical sequelae). Key discriminating findings: POD 3, low drain output (25 mL/24h), high drain amylase (1200 U/L), afebrile, hemodynamically stable, soft abdomen, no leukocytosis. The 2016 ISGPS criteria define this as a biochemical leak (Grade A) that can be managed by drain removal. The keyed answer (A) aligns with guideline-based management: removal is safe when output is low and the patient is clinically well. Option B (octreotide) is not indicated for a biochemical leak without clinical impact. Option C (CT) is unnecessary without signs of sepsis or clinical deterioration. Option D (discharge with drain) is inappropriate because the drain can be removed. Option E (reoperation) is reserved for clinically significant fistulas or sepsis. No contradictions or missing details prevent a unique best answer. The item is accurate and board-relevant.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": The question asks for the next step in management of a post-pancreaticoduodenectomy patient with a biochemical leak (drain fluid amylase >3× serum, low output, no clinical sequelae). Key discriminating findings: POD 3, low drain output (25 mL/24h), high drain amylase (1200 U/L), afebrile, hemodynamically stable, soft abdomen, no leukocytosis. The 2016 ISGPS criteria define this as a biochemical leak (Grade A) that can be managed by drain removal. The keyed answer (A) aligns with guideline-based management: removal is safe when output is low and the patient is clinically well. Option B (octreotide) is not indicated for a biochemical leak without clinical impact. Option C (CT) is unnecessary without signs of sepsis or clinical deterioration. Option D (discharge with drain) is inappropriate because the drain can be removed. Option E (reoperation) is reserved for clinically significant fistulas or sepsis. No contradictions or missing details prevent a unique best answer. The item is accurate and board-relevant.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-002", "question": "A 65-year-old man is diagnosed with high-grade T1 urothelial carcinoma of the bladder, 3 cm solitary lesion without carcinoma in situ. His EORTC risk score is 8. He is scheduled to begin intravesical BCG immunotherapy. What is the optimal evidence-based regimen?", "options": ["Induction only (6 weekly instillations)", "Induction plus 1-year maintenance", "Induction plus 3-year maintenance using Tice strain", "Induction plus 3-year maintenance using Connaught strain with first maintenance dose at 8 weeks", "Induction plus 2-year maintenance"], "answer": "D", "answer_index": 3, "explanation": "An EORTC score of 8 classifies high-risk disease mandating 3-year maintenance BCG. The Connaught strain demonstrates superior recurrence-free survival compared to Tice strain in meta-analyses. Maintenance must commence 8 weeks after induction completion. This regimen reduces recurrence by 37% compared to 1-year maintenance and is the standard of care for high-risk patients.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: The keyed answer (D) is not defensible due to a factual error in maintenance timing. Key stem clues—65-year-old, high-grade T1 urothelial carcinoma, EORTC risk score 8—correctly establish high-risk disease mandating 3-year BCG maintenance. While 3-year duration and potential Connaught strain superiority have some evidentiary support, the rationale's claim that maintenance must commence at 8 weeks is non-standard and incorrect: established EORTC and AUA protocols begin maintenance at 3 months (12 weeks). This factual inaccuracy renders option D incorrect. Option C (Tice strain) would be guideline-concordant on timing, but the item forces a choice based on strain superiority and incorrect timing. The item is therefore miskeyed: a unique best answer would require correct timing, but the key contains a critical error. Medical accuracy is compromised by this outdated protocol detail. Minimal fix: Revise option D to state 'first maintenance dose at 12 weeks' to align with guideline-based practice.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (D) is not defensible due to a factual error in maintenance timing. Key stem clues—65-year-old, high-grade T1 urothelial carcinoma, EORTC risk score 8—correctly establish high-risk disease mandating 3-year BCG maintenance. While 3-year duration and potential Connaught strain superiority have some evidentiary support, the rationale's claim that maintenance must commence at 8 weeks is non-standard and incorrect: established EORTC and AUA protocols begin maintenance at 3 months (12 weeks). This factual inaccuracy renders option D incorrect. Option C (Tice strain) would be guideline-concordant on timing, but the item forces a choice based on strain superiority and incorrect timing. The item is therefore miskeyed: a unique best answer would require correct timing, but the key contains a critical error. Medical accuracy is compromised by this outdated protocol detail. Minimal fix: Revise option D to state 'first maintenance dose at 12 weeks' to align with guideline-based practice.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. The vignette describes a patient on combined checkpoint inhibitor therapy who develops six watery stools per day, transaminase elevation (AST 180, ALT 220) with normal bilirubin, and endoscopic colitis. These findings point to immune‑related colitis and grade 2 hepatitis. The key management principle is high‑dose steroids (1 mg/kg prednisone) with addition of a second‑line agent only after 3–5 days of steroid failure. Infliximab is contraindicated in this setting because of hepatotoxicity risk, while vedolizumab lacks hepatic toxicity and is the preferred rescue therapy. Option C (steroids alone with conditional vedolizumab) aligns with current ASCO/NCCN guidelines and is the only choice that reflects the recommended stepwise approach. Options A and B inappropriately combine steroids with a biologic upfront; D offers observation alone, which is insufficient; E targets hepatitis rather than colitis. Thus a single best answer is defensible and the keyed answer is correct. Medical accuracy issue: The explanation incorrectly labels the colitis as “grade 3” when six stools per day meets CTCAE grade 2 criteria. This does not alter the management recommendation but is a factual inaccuracy. Minimal fix: Change the explanation to read “Grade 2 immune‑related colitis with concurrent grade 2 hepatitis…”\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. The vignette describes a patient on combined checkpoint inhibitor therapy who develops six watery stools per day, transaminase elevation (AST 180, ALT 220) with normal bilirubin, and endoscopic colitis. These findings point to immune‑related colitis and grade 2 hepatitis. The key management principle is high‑dose steroids (1 mg/kg prednisone) with addition of a second‑line agent only after 3–5 days of steroid failure. Infliximab is contraindicated in this setting because of hepatotoxicity risk, while vedolizumab lacks hepatic toxicity and is the preferred rescue therapy. Option C (steroids alone with conditional vedolizumab) aligns with current ASCO/NCCN guidelines and is the only choice that reflects the recommended stepwise approach. Options A and B inappropriately combine steroids with a biologic upfront; D offers observation alone, which is insufficient; E targets hepatitis rather than colitis. Thus a single best answer is defensible and the keyed answer is correct. Medical accuracy issue: The explanation incorrectly labels the colitis as “grade 3” when six stools per day meets CTCAE grade 2 criteria. This does not alter the management recommendation but is a factual inaccuracy. Minimal fix: Change the explanation to read “Grade 2 immune‑related colitis with concurrent grade 2 hepatitis…”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-004", "question": "A 45-year-old man with necrotizing pancreatitis is now 3 weeks from disease onset. Contrast-enhanced CT demonstrates a 9-cm walled-off necrosis in the lesser sac with a mature, well-defined wall. ERCP confirms disconnected pancreatic duct syndrome. He is febrile to 38.5°C with WBC 15,000 cells/µL. What is the definitive management?", "options": ["Immediate percutaneous catheter drainage", "Endoscopic ultrasound-guided cystgastrostomy now", "Surgical cystgastrostomy with necrosectomy now", "Delay intervention until 4 weeks then proceed endoscopically", "Continue antibiotics and observe"], "answer": "C", "answer_index": 2, "explanation": "The 2020 revised Atlanta guidelines permit intervention when WON demonstrates a mature wall, eliminating the mandatory 4-week wait. Disconnected pancreatic duct syndrome is a surgical indication because endoscopic drainage alone is associated with 40% recurrence. Surgical cystgastrostomy with necrosectomy definitively addresses both the necrosis and ductal disruption, reducing recurrence to <10%.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible). Verdict: The keyed answer C is not uniquely best; B and D are also defensible. Key stem clues: 3‑week necrotizing pancreatitis, 9‑cm walled‑off necrosis with a mature wall, ERCP‑confirmed disconnected pancreatic duct syndrome, fever and leukocytosis indicating infection. Main logical issue: The item permits several reasonable management pathways (immediate endoscopic drainage, immediate surgery, or delaying to 4 weeks) because current guidelines do not mandate surgery for DPDS and allow early endoscopic intervention if the wall is mature. Consequently, no single option is clearly superior. Main medical accuracy issue: The rationale cites outdated recurrence rates (≈40 % for endoscopic drainage, <10 % for surgery) that conflict with recent trials (e.g., PANTER 2018) showing lower recurrence with endoscopic approaches, and misstates that DPDS is an absolute surgical indication. Minimal fix: Revise option C to reflect a step‑up approach (e.g., \\\"Surgical cystgastrostomy only after failed endoscopic drainage\\\") and update the rationale to align with 2020 Atlanta guidelines and recent evidence.\",\n\"medical_accuracy_score\":  \t \t \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible). Verdict: The keyed answer C is not uniquely best; B and D are also defensible. Key stem clues: 3‑week necrotizing pancreatitis, 9‑cm walled‑off necrosis with a mature wall, ERCP‑confirmed disconnected pancreatic duct syndrome, fever and leukocytosis indicating infection. Main logical issue: The item permits several reasonable management pathways (immediate endoscopic drainage, immediate surgery, or delaying to 4 weeks) because current guidelines do not mandate surgery for DPDS and allow early endoscopic intervention if the wall is mature. Consequently, no single option is clearly superior. Main medical accuracy issue: The rationale cites outdated recurrence rates (≈40 % for endoscopic drainage, <10 % for surgery) that conflict with recent trials (e.g., PANTER 2018) showing lower recurrence with endoscopic approaches, and misstates that DPDS is an absolute surgical indication. Minimal fix: Revise option C to reflect a step‑up approach (e.g., \"Surgical cystgastrostomy only after failed endoscopic drainage\") and update the rationale to align with 2020 Atlanta guidelines and recent evidence.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem asks for the first immunosuppression change in a kidney transplant recipient with Banff class B BK virus nephropathy and viremia 18,000 copies/mL. Key clues: moderate biopsy findings, significant viremia (>10,000 threshold), and therapeutic tacrolimus trough. Current guidelines (KDIGO/AST) recommend antimetabolite reduction as the initial step to preserve calcineurin inhibitor backbone and balance rejection risk. Option B (reduce mycophenolate 50%) is the standard first modification; complete discontinuation (D) is reserved for persistent viremia, making B uniquely best. Option A is second-line per guidelines. Option C is illogical (switching CNIs without indication). Option E is incorrect as steroids should not be tapered initially. The item is well-specified: 'first modification' language distinguishes stepwise reduction from complete discontinuation. No internal contradictions. Medical content is accurate, modern, and board-relevant, correctly identifying mycophenolate as the agent most impairing viral clearance. No fix needed.\",\"medical_accuracy_score\":    \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem asks for the first immunosuppression change in a kidney transplant recipient with Banff class B BK virus nephropathy and viremia 18,000 copies/mL. Key clues: moderate biopsy findings, significant viremia (>10,000 threshold), and therapeutic tacrolimus trough. Current guidelines (KDIGO/AST) recommend antimetabolite reduction as the initial step to preserve calcineurin inhibitor backbone and balance rejection risk. Option B (reduce mycophenolate 50%) is the standard first modification; complete discontinuation (D) is reserved for persistent viremia, making B uniquely best. Option A is second-line per guidelines. Option C is illogical (switching CNIs without indication). Option E is incorrect as steroids should not be tapered initially. The item is well-specified: 'first modification' language distinguishes stepwise reduction from complete discontinuation. No internal contradictions. Medical content is accurate, modern, and board-relevant, correctly identifying mycophenolate as the agent most impairing viral clearance. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-006", "question": "A 62-year-old man with metastatic melanoma receives axicabtagene ciloleucel. On day 7 post-infusion, he develops confusion, expressive aphasia, and asterixis. He has a low-grade fever (37.8°C) only. ICE score is 8/10. EEG demonstrates triphasic waves. Brain MRI is normal. What is the immediate management?", "options": ["Tocilizumab 8 mg/kg intravenously once", "Dexamethasone 10 mg intravenously every 6 hours", "Methylprednisolone 1 g intravenously daily", "Tocilizumab plus dexamethasone 10 mg every 6 hours", "Supportive care with scheduled haloperidol"], "answer": "B", "answer_index": 1, "explanation": "An ICE score of 8 indicates grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS), which requires dexamethasone 10 mg IV q6h. Tocilizumab is indicated for cytokine release syndrome (CRS), not ICANS, and is unnecessary for grade 1 CRS. High-dose methylprednisolone is reserved for grade ≥3 ICANS. The EEG findings are characteristic but do not escalate management beyond standard ICANS algorithms.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: N (No answer defensible). Verdict: No option correctly addresses the clinical scenario per current ASTCT guidelines. The stem provides ICE score 8/10, which unequivocally indicates grade 1 ICANS, requiring supportive care without steroids. However, no option offers appropriate management: A treats CRS, not ICANS; B gives steroids appropriate for grade 2 but not grade 1; C gives high-dose steroids for severe disease; D combines unnecessary tocilizumab; and E inappropriately adds scheduled haloperidol to supportive care. The rationale's claim that ICE score 8 equals grade 2 is factually incorrect, making the item unsolvable as written. Medical accuracy is compromised by this core grading error, though the underlying treatment algorithm for grades 2-3 ICANS is correctly described. The low-grade fever does not justify tocilizumab for grade 1 CRS. Minimal fix: Change ICE score to 5/10 to reflect true grade 2 ICANS, making option B correct and unambiguous.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\": false,\"logical_false_reason\": \"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: N (No answer defensible). Verdict: No option correctly addresses the clinical scenario per current ASTCT guidelines. The stem provides ICE score 8/10, which unequivocally indicates grade 1 ICANS, requiring supportive care without steroids. However, no option offers appropriate management: A treats CRS, not ICANS; B gives steroids appropriate for grade 2 but not grade 1; C gives high-dose steroids for severe disease; D combines unnecessary tocilizumab; and E inappropriately adds scheduled haloperidol to supportive care. The rationale's claim that ICE score 8 equals grade 2 is factually incorrect, making the item unsolvable as written. Medical accuracy is compromised by this core grading error, though the underlying treatment algorithm for grades 2-3 ICANS is correctly described. The low-grade fever does not justify tocilizumab for grade 1 CRS. Minimal fix: Change ICE score to 5/10 to reflect true grade 2 ICANS, making option B correct and unambiguous.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 3}]